We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04931823
Recruitment Status : Recruiting
First Posted : June 18, 2021
Last Update Posted : December 19, 2022
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Information provided by (Responsible Party):
Conjupro Biotherapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 1, 2025
Estimated Study Completion Date : March 1, 2025
American Cancer Society. https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html Accessed 17 May 2022
NCCN Guidelines Version 1.2022, Management of Neutropenia
Pronk LC. Modulation of docetaxel treatment [dissertation], Rotterdam: Erasmus Universiteit; 1997
Taxotere® US Package Insert (version 11/2021)